Intracardiac and systemic hemodynamic parameters in patients with atrial fibrillation and flutter associated to arterial hypertension depending on lymphocytes and monocytes subpopulation characteristics and composition in peripheral blood
Main Article Content
Abstract
The aim – to compare intracardiac and systemic hemodynamic parameters in patients with paroxysmal and persistent forms of atrial fibrillation and atrial flutter associated with arterial hypertension, depending on the characteristics of peripheral blood lymphocyte and monocyte subpopulations.
Materials and methods. 147 patients were included into the study. Among them, 103 had atrial fibrillation or atrial flutter associated to arterial hypertension. Patients with rhythm disturbances were divided into three main groups:
group I – paroxysmal atrial fibrillation; group II – persistent atrial fibrillation; group III – persistent atrial flutter. Peripheral blood levels of lymphocyte and monocyte subpopulations were assessed using flow cytometry. Hemodynamic parameters were evaluated via transthoracic echocardiography, office blood pressure measurements, 24-hour ambulatory blood pressure monitoring, and transesophageal echocardiography. As controls, data from patients with arterial hypertension but without arrhythmias and from practically healthy individuals were used, forming groups IV and V, respectively.
Results and discussion. Analysis of lymphocyte subpopulations in groups I–III revealed that the absolute and relative numbers of cytotoxic cells (NK and NKT cells) were significantly higher compared with healthy individuals. A statistically significant reduction (p ≤ 0.05) in regulatory T-cell counts was observed in groups II and III comparing to controls.
Patients with AF and AFL on the background of hypertension demonstrated an increased number of classical and intermediate monocyte fractions compared with hypertensive patients without rhythm disturbances and healthy subjects.
Comparison of echocardiographic parameters between groups I–III and group IV revealed statistically significant differences (p ≤ 0.05) in left ventricular linear dimensions (end-diastolic diameter, end-systolic diameter, interventricular septal thickness, posterior wall thickness), transverse dimensions of the left atrium and right ventricle, early-to-late left ventricular filling velocity ratio (E/A), and left ventricular mass indices. Compared with group V, significant differences were observed only in end-systolic diameter, left atrial size, interventricular septal thickness, and posterior wall thickness. Office systolic blood pressure values were markedly higher in patients with arrhythmias. According to 24-hour blood pressure monitoring, significant differences were found in mean and maximal diastolic pressure.
Conclusions. Patients with atrial fibrillation and atrial flutter associated to arterial hypertension, compared to individuals without arrhythmias or healthy people, present elevated levels of pro-inflammatory monocyte subpopulations, increased numbers of cytotoxic T cells, and reduced levels of regulatory T cells. Echocardiographic data indicate more pronounced structural myocardial changes in these patients, including larger left atrial and left ventricular dimensions, increased interventricular septal and posterior wall thickness, and diastolic dysfunction. Measured systolic and diastolic blood pressure values differed significantly, indicating hemodynamic disturbances attributable both to rhythm disorders and to manifestations of arterial hypertension.
Article Details
Keywords:
References
Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century. Circulation Research. 2020;127:4–20 https://doi.org/10.1161/CIRCRESAHA.120.316340
Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of Atrial Fibrillation and Flutter in the United States. Am J Cardiol. 2009 Dec 1;104(11):1534-9. https://doi.org/10.1016/j.amjcard.2009.07.022
Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ 2018;361:k1453. https://doi.org/10.1136/bmj.k1453
Tsukamoto M, Seta N, Yoshimoto K, Suzuki K, Yamaoka K, Takeuchi T. CD14 bright CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis. Arthritis Res Ther. 2017 Feb 10;19(1):28. https://doi.org/10.1186/s13075-016-1216-6
Verdecchia P, Angeli F, Reboldi G. Hypertension and Atrial Fibrillation Doubts and Certainties From Basic and Clinical Studies. Circulation Res. 2018;122(2):352–368. https://doi.org/10.1161/circresaha.117.311402
Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacological Res. 2018;128:322–326. https://doi.org/10.1016/j.phrs.2017.10.007
Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? European Eur Heart J. 2006 Jan;27(2):136-49. https://doi.org/10.1093/eurheartj/ehi645
Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015 Apr;12(4):230-43. https://doi.org/10.1038/nrcardio.2015.2
Ziegler-Heitbrock L, Hofer TP. Toward a refined definition of monocyte subsets. Front Immunol. 2013 Feb 4;4:23. https://doi.org/10.3389/fimmu.2013.00023
Prabhu SD. It takes two to tango: monocyte and macrophage duality in the infarcted heart// Circ Res. 2014 May 9;114(10):1558–1560. https://doi.org/10.1161/CIRCRESAHA.114.3039
Sprangers S, de Vries TJ, Everts V. Monocyte Heterogeneity: Consequences for Monocyte-Derived Immune Cells. J Immunol Res. 2016;2016:1475435. https://doi.org/10.1155/2016/1475435
Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: Protagonists of Infarct Inflammation and Repair After Myocardial Infarction. Circulation. 2010;121:2437–2445. https://doi.org/10.1161/CIRCULATIONAHA.109.916346
Suzuki A, Fukuzawa K, Yamashita T, Yoshida A, Sasaki N, Emoto T, Takei A, Fujiwara R, Nakanishi T, et.al. Circulating intermediate CD14++CD16+monocytes are increased in patients with atrial fibrillation and reflect the functional remodelling of the left atrium. EP Europace. 2017 Jan;19(1):40-47. https://doi.org/10.1093/europace/euv422
Elcik D, Tuncay A, Bireciklioglu MF, İnanc MT. The importance of inflammation in atrial fibrillation recurrence in patients with atrial fibrillation treated with Cryo balloon ablation. Indian Pacing Electrophysiol J. 2025 Jan-Feb;25(1):14-19. https://doi.org/10.1016/j.ipej.2024.12.005
Zharinov OJ, Levchuk NP, Ikorkin MR, Sychov OS. Prognosing of prolonged sinus rhythm maintenance after cardioversion in patients with non valvular persistent atrial fibrillation. Lviv Clinical Bulletin. 20144(8):8-13. Ukrainian. https://doi.org/10.25040/lkv2014.04.008
Wałek P, Sielski J, Gorczyca I, Roskal-Wałek J, Starzyk K, Jaskulska-Niedziela E, et al. Left atrial mechanical remodelling assessed as the velocity of left atrium appendage wall motion during atrial fibrillation is associated with maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation. PLoS One. 2020 Jan 29;15(1):e0228239. https://doi.org/10.1371/journal.pone.0228239
Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022 Jan 20;8:798958. https://doi.org/10.3389/fmed.2021.798958
Khan AA, Thomas GN, Lip GYH, Shantsila A. Endothelial function in patients with atrial fibrillation. Ann Med. 2020 Feb-Mar;52(1-2):1-11. https://doi.org/10.1080/07853890.2019.1711158
Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev. 2005;10:31–7. https://doi.org/10.1007/s10741-005-2346-0
Zhang J, Yang L, Ding Y. Efects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy. BMC Cardiovasc Disord. 2021 Apr 20;21:194. https://doi.org/10.1186/s12872-021-02004-78
Kumar P, Saini S, Khan S, Surendra Lele S, Prabhakar BS. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. Cell Immunol. 2019 May;339:41-49. https://doi.org/10.1016/j.cellimm.2018.09.008
Bigdelou B, Sepand MR, Najafikhoshnoo S, Negrete JAT, Sharaf M, Ho JQ, Sullivan I, et al. COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. Front Immunol. 2022 May 27;13:890517. https://doi.org/10.3389/fimmu.2022.890517
Shahid F, Lip GYH, Shantsila E. Role of Monocytes in Heart Failure and Atrial Fibrillation. J Am Heart Assoc. 2018 Feb 1;7(3):e007849. https://doi.org/10.1161/jaha.117.007849
Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost. 2012 Jul;10(7):1231-41. https://doi.org/10.1111/j.1538-7836.2011.04603.x
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. 2020. Eur Heart J. 2021 Feb 1;42(5):373-498. https://doi.org/10.1093/eurheartj/ehaa612
Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis C, Tousoulis D. Inflammatory Mechanisms Contributing to Endothelial Dysfunction. Biomedicines. 2021 Jul 6;9(7):781. https://doi.org/10.3390/biomedicines9070781
Zheng E, Warchoł I, Mejza M, Możdżan M, Strzemińska M, Bajer A, Madura P, Żak J, Plewka M. Exploring Anti-Inflammatory Treatment as Upstream Therapy in the Management of Atrial Fibrillation. J Clin Med. 2025;14:882. https://doi.org/10.3390/jcm14030882
